Panacea Biotec is currently trading at Rs. 170.40, up by 7.40 points or 4.54% from its previous closing of Rs. 163.00 on the BSE.
The scrip opened at Rs. 170.40 and has touched a high and low of Rs. 177.75 and Rs. 169.65 respectively. So far 25659 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 181.95 on 18-Oct-2023 and a 52 week low of Rs. 107.15 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 177.75 and Rs. 162.40 respectively. The current market cap of the company is Rs. 998.39 crore.
The promoters holding in the company stood at 73.59%, while Institutions and Non-Institutions held 0.83% and 25.58% respectively.
Panacea Biotec has launched world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol, in India and received registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step-down wholly-owned subsidiary company viz. Panacea Biotec Germany GmbH, in Germany. EasyFourPol is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.
EasyFourPol is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic. It achieves the same level of protection as immunized with single-antigen vaccines, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. It leads to less vaccination and lesser shots for the child and greater comfort for the parents while ensuring better compliance for healthcare practitioners. Fewer shots also mean time saved for parents and more efficiency at points of vaccination. Additionally, it also helps reduce carbon emissions by reducing the need for vials, syringes, packaging material, and visits to vaccine administration centres.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1861.70 |
| Dr. Reddys Lab | 1389.35 |
| Cipla | 1506.15 |
| Lupin | 2228.00 |
| Zydus Lifesciences | 972.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
